Comparative Pharmacology
Head-to-head clinical analysis: MEZLIN versus PFIZERPEN A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEZLIN versus PFIZERPEN A.
MEZLIN vs PFIZERPEN-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mezlocillin is a ureidopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and activating autolytic enzymes.
3-4 g intravenously every 4-6 hours; maximum 24 g/day.
1-2 million units intramuscularly or intravenously every 4 hours; or continuous intravenous infusion of 20-30 million units per day.
None Documented
None Documented
Terminal elimination half-life is 0.7-1.2 hours in healthy adults; prolonged to 2-5 hours in renal impairment (CrCl <20 mL/min) and up to 10-20 hours in ESRD.
Terminal elimination half-life: 0.6-0.8 hours in adults with normal renal function; prolonged to 7-10 hours in end-stage renal disease (ESRD). In neonates, half-life ranges 2-4 hours.
Renal (70-80% unchanged via glomerular filtration and tubular secretion); biliary (approximately 2-3%); fecal (minor).
Primarily renal (60-70% unchanged via glomerular filtration and tubular secretion); hepatic metabolism minor (<10%); biliary/fecal elimination <10%.
Category C
Category C
Antibiotic (Penicillin)
Antibiotic (Penicillin)